1）Ferrara N：Vascular endothelial growth factor and age-related macular degeneration：from basic science to therapy. Nat Med 16：1107-1111, 2010
2）Miller JW, Le Couter J, Strauss EC et al：Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 120：106-114, 2013
3）Carmeliet P, Jain RK：Molecular mechanisms and clinical applications of angiogenesis. Nature 473：298-307, 2011
4）Ishida S, Shinoda K, Kawashima S et al：Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 41：1649-1656, 2000
5）Gragoudas ES, Adamis AP, Cunningham ET Jr et al：Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351：2805-2816, 2004
6）Rosenfeld PJ, Brown DM, Heier JS et al：Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355：1419-1431, 2006
7）Brown DM, Kaiser PK, Michels M et al：Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355：1432-1444, 2006
8）Friberg TR, Tolentino M, Weber P et al：Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration：the LEVEL study. Br J Ophthalmol 94：1611-1617, 2010
9）Varma R, Bressler NM, Suner I et al：Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion：results from the BRAVO and CRUISE trials. Ophthalmology 119：2108-2118, 2012
10）Nguyen QD, Brown DM, Marcus DM et al：Ranibizumab for diabetic macular edema：results from 2 phase Ⅲ randomized trials：RISE and RIDE. Ophthalmology 119：789-801, 2012
11）Michels S, Rosenfeld PJ, Puliafito CA et al：Systemic bevacizumab（Avastin）therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study, Ophthalmology 112：1035-1047, 2005
12）Martin DF, Maguire MG, Fine SL et al：Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration：two-year results. Ophthalmology 119：1388-1398, 2012
13）Gordon MS, Cunningham D：Managing patients treated with bevacizumab combination therapy. Oncology 69 Suppl 3：25-33, 2005
14）Ueta T, Yanagi Y, Tamaki Y et al：Cerebrovascular accidents in ranibizumab. Ophthalmology 116：362, 2009
15）Beyond cost considerations. Nat Med 18：835, 2012
16）Heier JS, Brown DM, Chong V et al：Intravitreal aflibercept（VEGF trap-eye）in wet age-related macular degeneration. Ophthalmology 119：2537-2548, 2012
17）Levine RJ, Maynard SE, Qian C et al：Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350：672-683, 2004
18）Li Y, Zhang F, Nagai N et al：VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 118：913-923, 2008
19）Murakami Y, Ikeda Y, Yonemitsu Y et al：Inhibition of choroidal neovascularization via brief subretinal exposure to a newly developed lentiviral vector pseudotyped with Sendai viral envelope proteins. Hum Gene Ther 21：199-209, 2010
20）Yafai Y, Yang XM, Niemeyer M et al：Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Eur J Pharmacol 666：12-18, 2011
, for age-related macular degeneration. Hum Gene Ther 23：980-991, 2012
22）Marneros AG, Keene DR, Hansen U et al：Collagen XVIII/endostatin is essential for vision and retinal pigment epithelial function. Embo J 23：89-99, 2004
23）Barnstable CJ, Tombran-Tink J：Neuroprotective and antiangiogenic actions of PEDF in the eye：molecular targets and therapeutic potential. Prog Retin Eye Res 23：561-577, 2004
24）Campochiaro PA, Nguyen QD, Shah SM et al：Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration：results of a phase Ⅰ clinical trial. Hum Gene Ther 17：167-176, 2006
25）Ikeda Y, Yonemitsu Y, Miyazaki M et al：Stable retinal gene expression in nonhuman primates via subretinal injection of SIVagm-based lentiviral vectors. Hum Gene Ther 20：573-579, 2009
ログイン
ランキング
お知らせ
ログイン
